Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Ekso Bionics Holdings (EKSO) over the last 11 years, with Q1 2025 value amounting to $180000.0.

  • Ekso Bionics Holdings' Asset Writedowns and Impairment rose 160000.0% to $180000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $278000.0, marking a year-over-year increase of 13166.67%. This contributed to the annual value of $171000.0 for FY2024, which is 13750.0% up from last year.
  • As of Q1 2025, Ekso Bionics Holdings' Asset Writedowns and Impairment stood at $180000.0, which was up 160000.0% from $98000.0 recorded in Q4 2024.
  • In the past 5 years, Ekso Bionics Holdings' Asset Writedowns and Impairment ranged from a high of $180000.0 in Q1 2025 and a low of -$12000.0 during Q1 2024
  • For the 5-year period, Ekso Bionics Holdings' Asset Writedowns and Impairment averaged around $33187.5, with its median value being $22000.0 (2021).
  • As far as peak fluctuations go, Ekso Bionics Holdings' Asset Writedowns and Impairment crashed by 130000.0% in 2024, and later soared by 160000.0% in 2025.
  • Over the past 5 years, Ekso Bionics Holdings' Asset Writedowns and Impairment (Quarter) stood at $27000.0 in 2021, then surged by 62.96% to $44000.0 in 2022, then increased by 6.82% to $47000.0 in 2023, then skyrocketed by 108.51% to $98000.0 in 2024, then surged by 83.67% to $180000.0 in 2025.
  • Its Asset Writedowns and Impairment was $180000.0 in Q1 2025, compared to $98000.0 in Q4 2024 and $34000.0 in Q3 2024.